MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference
NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 3rd Annual B. Riley Securities Oncology Conference on January 18th, at 11:00 AM ET.
- NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 3rd Annual B. Riley Securities Oncology Conference on January 18th, at 11:00 AM ET.
- Access to the live fireside chat is available at https://brileyoncology22.sequireevents.com/ .
- Following the fireside chat, a replay will be available on the Events and Presentations page of the MiNK website at https://investor.minktherapeutics.com/events-and-presentations .
- B. Riley Securities 3rd Annual Oncology Conference, January 18-19, will feature over 30 SMiD cap healthcare companies focused on the development and commercialization of new medicines and key enabling technologies, cutting across multiple next-generation therapeutic modalities.